Fapon Inaugurates State-of-the-Art R&D Center in Lexington, MA

November 11, 2023 11:36 PM AEDT | By Cision

Fapon Inaugurates State-of-the-Art R&D Center in Lexington, MA — Image source: Kalkine Media

Recent News

Capstone Copper Reports First Quarter 2025 Results

Atlassian Announces Third Quarter Fiscal Year 2025 Results

Amazon reports soft guidance after Q1 results beat

Amgen beats Q1 expectations, issues solid full-year outlook

LEXINGTON, Mass., Nov. 11, 2023 /PRNewswire/ -- Fapon, a global leading life sciences organization, is thrilled to announce the grand opening of its US-based Research and Development (R&D) Center, strategically located in Lexington, Massachusetts. This Center represents Fapon's unwavering commitment to advancing healthcare technologies and will further integrate the company into the local biotechnology ecosystem to accelerate growth.

The R&D Center will focus on advancing molecular diagnostic technologies and novel therapeutic platforms. Situated at the heart of the burgeoning biotechnology and pharmaceutical hub in Greater Boston, the new facility represents a pivotal milestone in Fapon's global discovery engine. It will serve as a strategic R&D center, uniting dedicated R&D, commercial, and corporate colleagues under one roof.

"In this Fapon Boston R&D center, we have created a hub for groundbreaking research, a sanctuary for the pursuit of knowledge, and a beacon of hope of molecular diagnosis and therapeutics for the future. This site affirms our commitment to advancing the frontiers of science and improving the lives of people around the world," said Nick Guan, Vice President of Fapon Life Sciences, a wholly-owned subsidiary of Fapon.

This purpose-built facility boasts spacious laboratories and offices, equipped with cutting-edge technology to facilitate innovation, incubation, and excellence. Furthermore, the strategic location near renowned academic, pharmaceutical, and biotechnology organizations strengthens prospects for collaboration to foster a culture of innovation.

Alex Wesselhoeft, Founder of Fapon's RNA technology incubation program, commented: "Innovative medical research requires significant operational, scientific, and financing support for successful execution. This incubator space will enable that risky first step on the path to delivering new medicines to patients."

Building on Fapon's long-standing commitment to innovation, the Company continuously invests in advanced technologies for its products and services to deliver value to customers and patients globally.

About Fapon

Fapon is a global leading life sciences company dedicated to providing integrated solutions and services for diagnostics, biopharma and biotherapy. Integrating a one-stop solution on raw materials, reagents and innovative open instrument platforms, the Company has grown into a leading supplier in in-vitro diagnostics. Fapon boasts advanced innovations in therapeutics technologies and AI algorithm platforms with data insights that contribute to a better and healthier world. Supported by its strong global R&D, manufacturing, sales and service network, Fapon's products have established presence in 68 countries and regions, serving more than 2,500 business partners worldwide.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.